tetano
Editor, Senior Moderator
Microorganisms
. 2022 Feb 4;10(2):362.
doi: 10.3390/microorganisms10020362.
Reactivation of Herpes Simplex Virus Type 1 (HSV-1) Detected on Bronchoalveolar Lavage Fluid (BALF) Samples in Critically Ill COVID-19 Patients Undergoing Invasive Mechanical Ventilation: Preliminary Results from Two Italian Centers
Daniele Roberto Giacobbe[SUP] 1 2 [/SUP], Stefano Di Bella[SUP] 3 [/SUP], Silvia Dettori[SUP] 1 2 [/SUP], Giorgia Brucci[SUP] 1 2 [/SUP], Verena Zerbato[SUP] 4 [/SUP], Riccardo Pol[SUP] 4 [/SUP], Ludovica Segat[SUP] 5 [/SUP], Pierlanfranco D'Agaro[SUP] 5 [/SUP], Erik Roman-Pognuz[SUP] 3 [/SUP], Federica Friso[SUP] 6 [/SUP], Luigi Principe[SUP] 7 [/SUP], Umberto Lucangelo[SUP] 6 [/SUP], Lorenzo Ball[SUP] 8 9 [/SUP], Chiara Robba[SUP] 8 9 [/SUP], Denise Battaglini[SUP] 9 10 [/SUP], Andrea De Maria[SUP] 1 2 [/SUP], Iole Brunetti[SUP] 9 [/SUP], Nicolò Patroniti[SUP] 8 9 [/SUP], Federica Briano[SUP] 1 2 [/SUP], Bianca Bruzzone[SUP] 11 [/SUP], Giulia Guarona[SUP] 11 [/SUP], Laura Magnasco[SUP] 2 [/SUP], Chiara Dentone[SUP] 2 [/SUP], Giancarlo Icardi[SUP] 1 11 [/SUP], Paolo Pelosi[SUP] 8 9 [/SUP], Roberto Luzzati[SUP] 3 [/SUP], Matteo Bassetti[SUP] 1 2 [/SUP]
Affiliations
Abstract
Reactivation of herpes simplex virus type 1 (HSV-1) has been described in critically ill patients with coronavirus disease 2019 (COVID-19) pneumonia. In the present two-center retrospective experience, we primarily aimed to assess the cumulative risk of HSV-1 reactivation detected on bronchoalveolar fluid (BALF) samples in invasively ventilated COVID-19 patients with worsening respiratory function. The secondary objectives were the identification of predictors for HSV-1 reactivation and the assessment of its possible prognostic impact. Overall, 41 patients met the study inclusion criteria, and 12/41 patients developed HSV-1 reactivation (29%). No independent predictors of HSV-1 reactivation were identified in the present study. No association was found between HSV-1 reactivation and mortality. Eleven out of 12 patients with HSV-1 reactivation received antiviral therapy with intravenous acyclovir. In conclusion, HSV-1 reactivation is frequently detected in intubated patients with COVID-19. An antiviral treatment in COVID-19 patients with HSV-1 reactivation and worsening respiratory function might be considered.
Keywords: BALF; COVID-19; HSV-1; SARS-CoV-2; herpes simplex virus; intensive care; reactivation.
. 2022 Feb 4;10(2):362.
doi: 10.3390/microorganisms10020362.
Reactivation of Herpes Simplex Virus Type 1 (HSV-1) Detected on Bronchoalveolar Lavage Fluid (BALF) Samples in Critically Ill COVID-19 Patients Undergoing Invasive Mechanical Ventilation: Preliminary Results from Two Italian Centers
Daniele Roberto Giacobbe[SUP] 1 2 [/SUP], Stefano Di Bella[SUP] 3 [/SUP], Silvia Dettori[SUP] 1 2 [/SUP], Giorgia Brucci[SUP] 1 2 [/SUP], Verena Zerbato[SUP] 4 [/SUP], Riccardo Pol[SUP] 4 [/SUP], Ludovica Segat[SUP] 5 [/SUP], Pierlanfranco D'Agaro[SUP] 5 [/SUP], Erik Roman-Pognuz[SUP] 3 [/SUP], Federica Friso[SUP] 6 [/SUP], Luigi Principe[SUP] 7 [/SUP], Umberto Lucangelo[SUP] 6 [/SUP], Lorenzo Ball[SUP] 8 9 [/SUP], Chiara Robba[SUP] 8 9 [/SUP], Denise Battaglini[SUP] 9 10 [/SUP], Andrea De Maria[SUP] 1 2 [/SUP], Iole Brunetti[SUP] 9 [/SUP], Nicolò Patroniti[SUP] 8 9 [/SUP], Federica Briano[SUP] 1 2 [/SUP], Bianca Bruzzone[SUP] 11 [/SUP], Giulia Guarona[SUP] 11 [/SUP], Laura Magnasco[SUP] 2 [/SUP], Chiara Dentone[SUP] 2 [/SUP], Giancarlo Icardi[SUP] 1 11 [/SUP], Paolo Pelosi[SUP] 8 9 [/SUP], Roberto Luzzati[SUP] 3 [/SUP], Matteo Bassetti[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35208817
- DOI: 10.3390/microorganisms10020362
Abstract
Reactivation of herpes simplex virus type 1 (HSV-1) has been described in critically ill patients with coronavirus disease 2019 (COVID-19) pneumonia. In the present two-center retrospective experience, we primarily aimed to assess the cumulative risk of HSV-1 reactivation detected on bronchoalveolar fluid (BALF) samples in invasively ventilated COVID-19 patients with worsening respiratory function. The secondary objectives were the identification of predictors for HSV-1 reactivation and the assessment of its possible prognostic impact. Overall, 41 patients met the study inclusion criteria, and 12/41 patients developed HSV-1 reactivation (29%). No independent predictors of HSV-1 reactivation were identified in the present study. No association was found between HSV-1 reactivation and mortality. Eleven out of 12 patients with HSV-1 reactivation received antiviral therapy with intravenous acyclovir. In conclusion, HSV-1 reactivation is frequently detected in intubated patients with COVID-19. An antiviral treatment in COVID-19 patients with HSV-1 reactivation and worsening respiratory function might be considered.
Keywords: BALF; COVID-19; HSV-1; SARS-CoV-2; herpes simplex virus; intensive care; reactivation.